公开(公告)号：US10377806B2

公开(公告)日：2019-08-13

申请号：US15979881

申请日：2018-05-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Paul E. Morin ,  Daniel Cohen ,  Ranjan Mukherjee ,  Timothy P. Reilly ,  Rose C. Christian ,  Dasa Lipovsek ,  Ray Camphausen ,  John Krupinski

IPC: A61K38/18 ,  C07K14/50 ,  A61K45/06 ,  A61K47/60 ,  A61K47/64 ,  A61K38/00

Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.

公开(公告)号：US10189883B2

公开(公告)日：2019-01-29

申请号：US15460917

申请日：2017-03-16

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Paul E. Morin ,  Daniel Cohen ,  Ranjan Mukherjee ,  Timothy P. Reilly ,  Rose C. Christian ,  Dasa Lipovsek ,  Ray Camphausen ,  John Krupinski

IPC: A61K38/18 ,  C07K14/50 ,  A61K45/06 ,  A61K47/60 ,  A61K38/00

Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.

公开(公告)号：US20180222960A1

公开(公告)日：2018-08-09

申请号：US15891492

申请日：2018-02-08

Applicant: Bristol-Myers Squibb Company

Inventor： Gene M. DUBOWCHIK ,  Olafur S. Gudmundsson ,  Xiaojun Han ,  R. Michael Lawrence ,  Dasa Lipovsek ,  Cort S. Madsen ,  Claudio Mapelli ,  Paul E. Morin ,  Michael C. Myers

IPC: C07K14/64 ,  C07K1/107 ,  A61P9/00 ,  A61K47/64

CPC classification number: C07K14/64 ,  A61K38/00 ,  A61K45/06 ,  A61K47/64 ,  A61P9/00 ,  C07K1/1077

Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

公开(公告)号：US12194110B2

公开(公告)日：2025-01-14

申请号：US17483393

申请日：2021-09-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Paul E. Morin ,  David Donnelly ,  Dasa Lipovsek ,  Jochem Gokemeijer ,  Maria N. Jure-Kunkel ,  David Fabrizio ,  Martin C. Wright ,  Douglas Dischino ,  Samuel J. Bonacorsi, Jr. ,  Ralph Adam Smith ,  Virginie Lafont ,  Daniel Cohen

IPC: A61K51/08 ,  C07K14/78 ,  C12N5/00 ,  C12N15/09 ,  G01N33/574 ,  G01N33/60 ,  G01N33/68

Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.

公开(公告)号：US20220331402A1

公开(公告)日：2022-10-20

申请号：US17721569

申请日：2022-04-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Gene M. Dubowchik ,  Olafur S. Gudmundsson ,  Xiaojun Han ,  R. Michael Lawrence ,  Dasa Lipovsek ,  Cort S. Madsen ,  Claudio Mapelli ,  Paul E. Morin ,  Michael C. Myers

IPC: A61K38/18 ,  C07K14/64 ,  C07K1/107 ,  A61K38/22

Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

公开(公告)号：US11224634B2

公开(公告)日：2022-01-18

申请号：US17198939

申请日：2021-03-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Gene M. Dubowchik ,  Olafur S. Gudmundsson ,  Xiaojun Han ,  R. Michael Lawrence ,  Dasa Lipovsek ,  Cort S. Madsen ,  Claudio Mapelli ,  Paul E. Morin ,  Michael C. Myers

IPC: A61K38/22 ,  A61K38/18 ,  C07K14/64 ,  C07K1/107 ,  A61K38/00 ,  A61K47/64 ,  A61P9/00 ,  A61K45/06

Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

公开(公告)号：US11185570B2

公开(公告)日：2021-11-30

申请号：US16287342

申请日：2019-02-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Gene M. Dubowchik ,  Olafur S. Gudmundsson ,  Xiaojun Han ,  R. Michael Lawrence ,  Dasa Lipovsek ,  Cort S. Madsen ,  Claudio Mapelli ,  Paul E. Morin ,  Michael C. Myers

IPC: A61K38/18 ,  C07K14/64 ,  C07K1/107 ,  A61K38/00 ,  A61K47/64 ,  A61P9/00 ,  A61K45/06

Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

公开(公告)号：US11173219B2

公开(公告)日：2021-11-16

申请号：US16520965

申请日：2019-07-24

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Paul E. Morin ,  David Donnelly ,  Dasa Lipovsek ,  Jochem Gokemeijer ,  Maria Jure-Kunkel ,  David Fabrizio ,  Martin C. Wright ,  Douglas Dischino ,  Samuel J. Bonacorsi, Jr. ,  Ralph Adam Smith ,  Virginie LaFont ,  Daniel Cohen

IPC: A61K51/08 ,  C07K14/78 ,  G01N33/574 ,  C12N5/00 ,  C12N15/09 ,  G01N33/60 ,  G01N33/68

Abstract: Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.

公开(公告)号：US10934572B2

公开(公告)日：2021-03-02

申请号：US16244921

申请日：2019-01-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Michael L. Gosselin ,  David Fabrizio ,  Joanna F. Swain ,  Tracy Mitchell ,  Ray Camphausen ,  Sharon T. Cload ,  Eric Furfine ,  Paul E. Morin ,  Ranjan Mukherjee ,  Simeon I. Taylor

IPC: C12P21/00 ,  C12N15/62 ,  A61K47/62 ,  A61K47/64 ,  C07K14/78 ,  C07K14/435 ,  C07K14/50 ,  C07K14/575 ,  A61K38/00

Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

公开(公告)号：US20190382460A1

公开(公告)日：2019-12-19

申请号：US16455990

申请日：2019-06-28

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Paul E. Morin ,  Daniel Cohen ,  Ranjan Mukherjee ,  Timothy P. Reilly ,  Rose C. Christian ,  Dasa Lipovsek ,  Ray Camphausen ,  John Krupinski

IPC: C07K14/50 ,  A61K45/06 ,  A61K47/60 ,  A61K38/18 ,  A61K47/64

Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.